Press Releases
Recent Press Releases
Miravo Healthcare™ Announces Director Election Results of its Annual Meeting of Shareholders
May 16, 2022Miravo Healthcare™ Announces First Quarter 2022 Results
May 16, 2022Miravo Healthcare™ Provides an Update on the United States Pennsaid® 2% Business
May 12, 2022Miravo Healthcare™ Announces First Quarter 2022 Results Release Date and Virtual Annual Meeting of Shareholders
May 2, 2022Archived Press Releases
April 19, 2022
Miravo Healthcare™ to Present at Bloom Burton & Co. Healthcare Investor Conference
Miravo Healthcare™ Acknowledged In The Globe and Mail’s
Third-Annual Women Lead Here
Benchmark of Executive Gender Diversity
March 14, 2022
Miravo Healthcare™ Announces
Fourth Quarter 2021 Results Release Date and
Conference Call Details
March 1, 2022
Miravo Healthcare™ Announces
the Canadian Commercial Launch of Blexten®
for Patients 4 Years of Age and Older
February 28, 2022
Miravo Healthcare™ Announces Summary Judgment Ruling by
the United States District Court for the District of New Jersey
February 28, 2022
Miravo Healthcare™ to Present at
Q1 Virtual Investor Summit
January 24, 2022
Miravo HealthcareTM Named to 2022 OTCQX Best 50
January 6, 2022
Miravo HealthcareTM Announces Participation at the H.C. Wainwright Bioconnect Conference
November 24, 2021
Miravo HealthcareTM Presents at the SNN Network Canada Virtual Event
November 18, 2021
Miravo HealthcareTM to Host Investor Webcast on December 2, 2021 at 2:00 p.m. ET
November 15, 2021
Miravo HealthcareTM Announces Third Quarter 2021 Results
November 1, 2021
Miravo HealthcareTM Announces Third Quarter 2021 Results Release Date and Conference Call Details
September 7, 2021
Miravo HealthcareTM Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference
August 12, 2021
Miravo HealthcareTM Announces Receipt of Health Canada Notice of Compliance for the Pediatric use of Blexten
August 9, 2021
Miravo HealthcareTM Announces Second Quarter 2021 Results
July 29, 2021
Miravo HealthcareTM Ireland Enters into Suvexx License and Supply Agreement with SK Chemicals Co., Ltd. for South Korea
July 26, 2021
Miravo HealthcareTM Announces Second Quarter 2021 Results Release Date and Conference Call Details
July 8, 2021
Miravo HealthcareTM to Present at Access to Giving Virtual Investor Conference
May 27, 2021
Miravo HealthcareTM to Present at Summer Solstice - Best Ideas from the Buy Side
May 19, 2021
Miravo HealthcareTM Announces Appointment of Mary Ritchie to its Board of Directors
May 17, 2021
Miravo HealthcareTM Announces Director Election Results of its Annual Meeting of Shareholders
May 17, 2021
Miravo HealthcareTM Announces First Quarter 2021 Results
May 11, 2021
Miravo HealthcareTM to Present at Q2 Virtual Investor Summit
Apri 21, 2021
Miravo HealthcareTM Files Final Base Shelf Prospectus
Apri 9, 2021
Miravo HealthcareTM to Present at Upcoming Investor Conferences
March 26, 2021
Miravo HealthcareTM Acknowledged in the Globe and Mail's Second Annual Women Lead Here Benchmark of Executive Gender Diversity
March 11, 2021
Miravo HealthcareTM to Present at Q1 Virtual Investor Summit
March 8, 2021
Miravo HealthcareTM Announces Fourth Quarter 2020 Results
March 8, 2021
Miravo HealthcareTM Files Preliminary Base Shelf Prospectus
February 22, 2021
Miravo HealthcareTM Announces Fourth Quarter 2020 Results Release Date and Conference Call Details
January 14, 2021
Miravo HealthcareTM to Host Investor Webcast on January 28, 2021 at 2:00 pm EST
December 21, 2020
Miravo HealthcareTM Ireland Enters into Suvexx®
License and Supply Agreement with Orion Corporation for Select EU Markets
December 18, 2020
Nuvo Pharmaceuticals®
Announces Corporate Rebranding as Miravo Healthcare
November 16, 2020
Nuvo Pharmaceuticals®
Announces Third Quarter 2020 Results
November 2, 2020
Nuvo Pharmaceuticals®
Announces Third Quarter 2020 Results Release Date and Conference Call
October 5, 2020
Nuvo Pharmaceuticals®
to Webcast Live at VirtualInvestorConferences.com October 8th
September 14, 2020
Nuvo Pharmaceuticals® to Webcast Live at Life Sciences Investor Forum September 17th
September 9, 2020
Nuvo Pharmaceuticals® Announces The Canadian Commercial Launch of Suvexx™ - For The Acute Treatment of Migraine
August 10, 2020
Nuvo Pharmaceuticals® Announces Second Quarter 2020 Results
July 27, 2020
Nuvo Pharmaceuticals™ Announces Second Quarter 2020 Results Release Date and Conference Call Details
May 12, 2020
Nuvo Pharmaceuticals® Announces Director Election Results of its Annual & Special Meeting of Shareholders
May 11, 2020
Nuvo Pharmaceuticals® Announces First Quarter 2020 Results
April 27, 2020
Nuvo Pharmaceuticals® Announces First Quarter 2020 Results Release Date and Virtual Annual & Special Meeting of Shareholders
March 23, 2020
Nuvo Pharmaceuticals® to Webcast Live at Life Sciences Investor Forum March 26th
March 4, 2020
Nuvo Pharmaceuticals® Announces "at risk" Launch of Generic Version of Vimovo in the United States
February 27, 2020
Nuvo Pharmaceuticals® Announces Health Canada Approves Suvexx™ For The Acute Treatment of Migraine
February 25, 2020
Nuvo Pharmaceuticals® Announces 2019 and Fourth Quarter Results
February 11, 2020
Nuvo Pharmaceuticals™ Responds to Market Activity
February 11, 2020
Nuvo Pharmaceuticals™ Announces Fourth Quarter 2019 Results Release Date and Conference Call Details
January 7, 2020
Nuvo Pharmaceuticals™ Announces Repayment of Bridge Loan and Entitlement to Receive 2019 Vimovo U.S. Annual Minimum Royalty
October 31, 2019
Nuvo Pharmaceuticals™ Announces 2019 Third Quarter Results
October 17, 2019
Nuvo Pharmaceuticals™ Announces Third Quarter 2019 Results Release Date and Conference Call Details
September 9, 2019
Nuvo Pharmaceuticals™ Update to Nuvo's Presentation Time at H.C. Wainwright Global Investment Conference
September 4, 2019
Nuvo Pharmaceuticals™ to Present at H.C. Wainwright Global Investment Conference
August 14, 2019
Nuvo Pharmaceuticals™ Announces 2019 Second Quarter Results
July 31, 2019
Nuvo Pharmaceuticals™ Announces Second Quarter 2019 Results Release Date and Conference Call Details
July 30, 2019
Nuvo Pharmaceuticals™ Provides VIMOVO Patent Update
June 17, 2019
Nuvo Pharmaceuticals™ Provides Corporate Update
May 14, 2019
Nuvo Pharmaceuticals™ Announces 2019 First Quarter Results
April 23, 2019
Nuvo Pharmaceuticals™ to Present at the Bloom Burton & Co. Healthcare Investor Conference
March 29, 2019
Nuvo Pharmaceuticals™ Announces 2018 Fourth Quarter and Year-End Results
January 3, 2019
Nuvo Pharmaceuticals™ Announces Appointment of Rob Harris as Executive Chairman
December 31, 2018
Nuvo Pharmaceuticals™ Announces Completion of the Acquisition of Aralez Pharmaceuticals Canada, U.S. and International Rights to Vimovo® and other Related Assets
December 21, 2018
Nuvo Pharmaceuticals™ (Ireland) DAC Enters into Resultz® License and Supply Agreement with Heumann Pharma GmbH & Co. Generica KG for Germany
November 29, 2018
Nuvo Pharmaceuticals™ Pharmaceuticals™ Declared Winning Bidder to Acquire Commercial Products from Aralez Pharmaceuticals
November 8, 2018
Nuvo Pharmaceuticals™ Announces 2018 Third Quarter Results
September 19, 2018
Nuvo Pharmaceuticals™ Announces Signing of Definitive Agreements to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals
August 20, 2018
Nuvo Pharmaceuticals™ Announces Extension of Exclusivity Period with Aralez and Deerfield
August 10, 2018
Nuvo Pharmaceuticals™ Announces Letter of Intent to Acquire Commercial Products and Infrastructure from Aralez Pharmaceuticals
August 2, 2018
Nuvo Pharmaceuticals™ Announces 2018 Second Quarter Results
May 10, 2018
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting
May 10, 2018
Nuvo Pharmaceuticals™ Announces 2018 First Quarter Results
March 23, 2018
Nuvo Pharmaceuticals™ Announces 2017 Fourth Quarter
January 15, 2018
Nuvo Pharmaceuticals (Ireland) Limited Acquires U.S. Product Rights to Resultz® from Piedmont Pharmaceuticals LLC
January 2, 2018
Nuvo Pharmaceuticals Inc.™ Acquires Global ex-U.S. Product Rights and existing Royalty Streams to Resultz® from Piedmont Pharmaceuticals LLC